Skip to content
ATLAS PREP HQ
Cosmetic

SNAP-8

Acetyl octapeptide-3, a SNAP-25-mimetic cosmetic peptide

Cosmetic peptide research focused on facial-expression lines and wrinkle appearance.

Preclinical Evidence

Route

Topical is the relevant cosmetic route. Subcutaneous injection is experimental and lacks a clinical evidence base.

Common format

10 mg vial

Research focus

expression lines

Evidence level

Preclinical Evidence

Typical cycle

4–8 weeks (topical)

Cosmetic research motifCosmetic

SNAP-8 in 30 seconds

Atlas Fast Read

What it is

Acetyl octapeptide-3, a SNAP-25-mimetic cosmetic peptide

Why people care

Cosmetic peptide research focused on facial-expression lines and wrinkle appearance.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Evidence is formulation-specific and topical. It is unknown whether injectable exposure is safe or useful, what systemic pharmacology would occur, and whether cosmetic effects outperform standard topical care.

Bottom line

SNAP-8 belongs primarily in topical cosmetic science.

Overview

What is SNAP-8?

SNAP-8 is acetyl octapeptide-3, a SNAP-25-mimetic cosmetic peptide. Cosmetic peptide research focused on facial-expression lines and wrinkle appearance.

Acetyl octapeptide-3 was commercialized in the 2000s as a topical cosmetic peptide related to Argireline. Its development history is cosmetic, not injectable drug development.

Mechanism

How it works

Designed to mimic the N-terminal region of SNAP-25 and compete within the SNARE complex, theoretically reducing acetylcholine vesicle release at superficial neuromuscular junctions. Evidence is primarily topical/cosmetic.

Research areas

expression linestopical cosmetic peptidesSNARE signalingskin aging

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Human evidence exists mainly for topical cosmetic formulations containing acetyl octapeptide-3 and related expression-line peptides. Evidence for injectable SNAP-8 is absent, and topical studies are generally small and formulation-specific.

Preclinical evidence

In vitro work supports interference with SNARE/SNAP-25-related neurotransmitter release, and cosmetic formulation studies suggest possible reduction in expression-line appearance. Injectable pharmacology is not established.

Knowledge gaps

Evidence is formulation-specific and topical. It is unknown whether injectable exposure is safe or useful, what systemic pharmacology would occur, and whether cosmetic effects outperform standard topical care.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

No validated injectable human dose exists. The meaningful human/cosmetic use case is topical acetyl octapeptide-3 at formulation-specific concentrations. Community sources list an experimental SC 330–1,000 mcg/day protocol, but that is not supported by established clinical practice.

Frequency

Topical products are generally used according to cosmetic formulation directions; no evidence-based injectable frequency exists.

Timing

Topical timing follows skincare routine; no pharmacologic time-of-day requirement is established.

Route

Topical is the relevant cosmetic route. Subcutaneous injection is experimental and lacks a clinical evidence base.

Cycle length

4–8 weeks (topical)

Reconstitution

For topical raw material, formulation should follow a qualified cosmetic chemist/manufacturer. the community 1 mL/10 mg SC research-vial instruction is not a validated clinical route.

Storage

Follow the peptide/formulation manufacturer's stability instructions; avoid heat/light and contamination after formulation.

Monitoring

Monitor skin irritation, dermatitis and objective wrinkle/skin outcomes. There is no systemic lab-monitoring standard for topical cosmetic use.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Topical products can cause local irritation or dermatitis. Systemic/injectable adverse effects are unknown because injectable SNAP-8 is not an established human treatment.

Contraindications

Topical use should be avoided on irritated/broken skin or with ingredient hypersensitivity. Injectable use has no established safety profile and should not be treated as a validated cosmetic therapy.

Interactions

Topical interactions are mainly irritation-related with other active skincare ingredients. There are no reliable systemic drug-interaction data for injectable use.

Stacks

Common stacks

Topical skincare formulation

The meaningful context is topical cosmetic formulation rather than injectable peptide stacking.

Formulation-specific cosmetic evidence; no systemic stack established.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

SNAP-8 belongs primarily in topical cosmetic science. Atlas would keep the conversation there; injectable protocols are not supported by an established human evidence base.